SEC Form 4 · accession 0001213900-15-004133
Actinium Pharmaceuticals, Inc. · ATNM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dragan Cicic
Officer — COO and Chief Medical Officer
Period of report
May 7, 2015
Accepted (ET)
May 22, 2015 · 5:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001388320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF1 | May 7, 2015 | F | 560 | $2.52 | D | 560 | D | |
| Common stock | May 7, 2015 | D | 2,380 | $2.52 | D | 560 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to purchase common stock | $2.52 | May 7, 2015 | A | 2,874 | A | May 7, 2015 | May 7, 2025 | Common stock | 2,874 | 2,874 | D |
Explanation of responses
- F1Recipient was granted 3,500 shares of restricted common stock on 2/21/14. As of May 7, 2015, 1,120 shares were vested. Company withheld 560 shares to pay tax obligations of award recipient on vested shares. The remaining 2,380 unvested shares of restricted stock were cancelled and a new award of 2,874 options exercisable for shares of common stock were granted to the recipient.